EyePoint restructuring plans announced on October 19, 2026, call for cutting roughly 53% of the workforce and halting ongoing pivotal wet age-related macular degeneration trial work as the company prioritizes Duravyu for diabetic macular edema. The cost-reduction plan follows a second Phase 3 wet AMD trial that failed its primary vision endpoint.
Key Takeaways
- EyePoint plans to reduce its workforce by roughly 53% as it redirects development resources.
- Duravyu missed the primary endpoint in LUCIA, despite favorable secondary findings.
- Management expects pivotal DME results from COMO and CAPRI in the fourth quarter of 2027.
Table of Contents
- EyePoint restructuring shifts resources toward DME
- LUCIA misses the main vision test
- DME results remain a future milestone
- Conclusion
EyePoint restructuring shifts resources toward DME
The clinical-stage biotechnology company is concentrating on diabetic macular edema, or DME, rather than continuing its pivotal wet AMD program as previously planned. Both programs evaluate Duravyu, an investigational sustained-delivery treatment containing vorolanib.
The workforce reduction is an announced plan, not a confirmed completed reduction. Its stated purpose is to lower costs and prioritize late-stage DME development; the supplied information does not quantify expected savings or restructuring charges.
Stopping ongoing pivotal trial work does not mean the company has finished evaluating the wet AMD findings. EyePoint said it would conduct additional analyses of LUCIA and the pooled Phase 3 datasets to assess possible next steps for that indication.
| Item | Details |
|---|---|
| LUCIA enrollment | 475 patients |
| LUGANO enrollment | 432 patients |
| Wet AMD Duravyu regimen | 2.7 mg every 24 weeks, with supplemental aflibercept as needed |
| Wet AMD control regimen | On-label aflibercept 2 mg every eight weeks |
LUCIA misses the main vision test
EyePoint’s October 19 LUCIA results announcement states that Duravyu did not establish statistical non-inferiority to on-label aflibercept in the change in best-corrected visual acuity. The trial showed visual improvement, but that was not sufficient to meet its predefined primary endpoint.
The earlier LUGANO trial also missed its primary endpoint in the full dataset. Together, the two results leave the wet AMD program without a successful primary-endpoint outcome from either pivotal study.
EyePoint nevertheless reported favorable secondary findings, including reduced treatment burden, anatomical control and safety with repeat dosing. More than half of Duravyu patients remained free of supplemental injections through 56 weeks in both trials. Those findings do not reverse the primary-endpoint failures.
DME results remain a future milestone
EyePoint continues to advance the pivotal COMO and CAPRI studies in DME, with topline results expected in the fourth quarter of 2027. That timing is management’s expectation, not a completed clinical result.
The company’s confidence rests partly on the Phase 2 VERONA study, which met its primary endpoint of extending time to the first supplemental injection compared with aflibercept for both Duravyu doses. Earlier-stage success, however, does not establish that the Phase 3 studies will succeed.
Duravyu remains investigational and has not been approved by the U.S. Food and Drug Administration. The restructuring therefore concentrates resources on another clinical development program, rather than an approved product.
Conclusion
The next scheduled major clinical milestone is the expected fourth-quarter 2027 release of COMO and CAPRI topline results. Those studies will test whether the DME program can support EyePoint’s narrower development focus.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
